secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0001654954-23-004872
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports preliminary Q1 2023 net loss of $2.8M; no revenue
-----------------------------------------------------------------------------

- Expects no revenue for Q1 2023, consistent with Q1 2022.
- Net loss approximately $2.8M, improving from $2.9M loss in prior year.
- Cash and cash equivalents $2.4M; total assets $6.7M; working capital $4.3M.
- Filed S-1/A for underwritten public offering of common stock and warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/0001654954-23-004872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-004872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer